Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the iShares U.S. Pharmaceuticals ETF (IHE) , a passively managed exchange traded fund launched on May 1, 2006.Retail and institutional investors increasingly turn to passively managed ETFs because they offer low costs, transparency, flexibility, and tax efficiency; these kind of funds are also excellent vehicles for long term investors.Sector ETFs also provide investors access to a broad group of companie ...

Core Viewpoint - The Invesco Pharmaceuticals ETF (PJP) provides broad exposure to the Healthcare - Pharma segment, appealing to both retail and institutional investors due to its low costs, transparency, flexibility, and tax efficiency [1][2]. Fund Overview - PJP is a passively managed ETF launched on June 23, 2005, with assets exceeding $257.58 million, positioning it as an average-sized ETF in the Healthcare - Pharma sector [3]. - The fund aims to match the performance of the Dynamic Pharmaceutical Intellidex Index, which evaluates U.S. pharmaceutical companies based on various investment criteria [4]. Cost Structure - The annual operating expenses for PJP are 0.56%, which is competitive within its peer group, and it has a 12-month trailing dividend yield of 1.07% [5]. Sector Exposure and Holdings - PJP is fully allocated to the Healthcare sector, with Eli Lilly & Co (LLY) making up approximately 5.24% of total assets, followed by Pfizer Inc (PFE) and Amgen Inc (AMGN). The top 10 holdings constitute about 47.34% of total assets [6][7]. Performance Metrics - Year-to-date, PJP has increased by roughly 9.35%, and it was up about 6.41% over the last 12 months as of August 19, 2025. The ETF has traded between $74.593 and $90.012 in the past 52 weeks, with a beta of 0.48 and a standard deviation of 15.82% over the trailing three-year period [8]. Alternatives - PJP holds a Zacks ETF Rank of 3 (Hold), indicating it is a viable option for investors seeking exposure to the Healthcare ETFs market. Other alternatives include the VanEck Pharmaceutical ETF (PPH) and the iShares U.S. Pharmaceuticals ETF (IHE), which have assets of $532.51 million and $571.47 million, respectively, with lower expense ratios of 0.36% and 0.39% [9][10].

Core Insights - The VanEck Pharmaceutical ETF (PPH) offers broad exposure to the Healthcare - Pharma segment, appealing to both institutional and retail investors due to its low cost and transparency [1][2] - The fund has assets exceeding $497.25 million and aims to match the performance of the MVIS US Listed Pharmaceutical 25 Index [3][4] Costs - PPH has an annual operating expense ratio of 0.36%, making it one of the cheaper options in the ETF space, with a 12-month trailing dividend yield of 2.27% [5] Sector Exposure and Top Holdings - The ETF's top holding is Eli Lilly & Co (LLY), which constitutes approximately 18.57% of total assets, followed by Johnson & Johnson (JNJ) and Novartis Ag (NVS). The top 10 holdings represent about 73.03% of total assets [6] Performance and Risk - As of July 22, 2025, PPH has a return of roughly 0.81% and is down about -4.46% year-to-date. The ETF has traded between $80.28 and $99.43 over the past 52 weeks, with a beta of 0.54 and a standard deviation of 14% for the trailing three-year period, indicating medium risk [7] Alternatives - PPH carries a Zacks ETF Rank of 3 (Hold), suggesting it is a reasonable option for investors seeking exposure to the Healthcare ETFs market. Other alternatives include Invesco Pharmaceuticals ETF (PJP) and iShares U.S. Pharmaceuticals ETF (IHE) [8][9]

Core Viewpoint - The Invesco Pharmaceuticals ETF (PJP) is a smart beta ETF designed to provide broad exposure to the healthcare sector, specifically focusing on U.S. pharmaceutical companies [1][5][6]. Fund Overview - PJP was launched on June 23, 2005, and has accumulated over $239.95 million in assets, categorizing it as an average-sized ETF within the healthcare sector [1][5]. - The fund aims to match the performance of the Dynamic Pharmaceutical Intellidex Index, which evaluates companies based on various investment merit criteria [5][6]. Cost and Expenses - PJP has an annual operating expense ratio of 0.56%, which is competitive with most peer products in the healthcare ETF space [7]. - The fund offers a 12-month trailing dividend yield of 1.16% [7]. Sector Exposure and Holdings - The ETF is fully allocated to the healthcare sector, with approximately 100% of its portfolio dedicated to this area [8]. - Eli Lilly & Co (LLY) constitutes about 5.41% of the fund's total assets, followed by Amgen Inc (AMGN) and Pfizer Inc (PFE). The top 10 holdings represent approximately 46.64% of total assets [9]. Performance Metrics - As of July 10, 2025, PJP has gained roughly 0.8% year-to-date and approximately 2.82% over the past year [11]. - The fund has traded between $74.59 and $89.61 in the last 52 weeks, with a beta of 0.47 and a standard deviation of 15.71% over the trailing three-year period, indicating a higher risk profile compared to peers [11]. Alternatives - Other ETFs in the pharmaceutical space include iShares U.S. Pharmaceuticals ETF (IHE) and VanEck Pharmaceutical ETF (PPH), which have lower expense ratios of 0.39% and 0.36%, respectively [13]. - Investors seeking lower-risk options may consider traditional market cap weighted ETFs that aim to match healthcare sector returns [13].